Forging the way for tomorrow’s innovations today
Genmab’s leadership team includes the company’s co-founder and Chief Executive Officer, the Chief Financial Officer, the Chief Operating Officer and the Chief Development Officer, who together lead more than 700 employees to achieve our vision.
With their passion for innovation, deep understanding of the antibody field and proven business acumen, our senior leaders bring their combined know-how to guide the company’s continued growth trajectory.
Learn more about our senior leaders by clicking on their names.
Jan G. J. van de Winkel, Ph.D.
President & Chief Executive Officer
Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications.
Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University. He is chairman of the board of directors of Hookipa Pharma, and a member of the board of directors of LEO Pharma and Omega Alpha SPAC. He holds M.S. and Ph.D. degrees from the University of Nijmegen.
Judith Klimovsky, M.D.
Executive Vice President & Chief Development Officer
Dr. Klimovsky joined Genmab in 2017 and is a recognized drug developer with more than 20 years of experience in R&D leadership roles in big pharma. She has successfully led the development of key cancer drugs at both Bristol Myers Squibb and Novartis, from early clinic through late-stage development and approval including ixabepilone (BMS), ASA404, MEK162, LGX818 and Afinitor (Novartis). During the span of her career, she has led global development organizations of over 450 people.
Dr. Klimovsky has been a board member of Bellicum Pharmaceuticals since January 2019. Previously, Dr. Klimovsky served in various hematology clinical practice positions in Buenos Aires, Argentina. Dr. Klimovsky earned her M.D. from the Buenos Aires University School of Medicine. As a medical doctor, she also brings skills and experience from working as a clinician in hospital environments.
Argentinian (U.S. Citizen)
Executive Vice President & Chief Operating Officer
Mr. Mancini joined Genmab in March 2020 as Executive Vice President and Chief Operating Officer. He is responsible for ensuring Genmab brings its innovative and differentiated medicines to patients around the world and for leading Genmab’s Commercial, Corporate Development, Business Development and Information Technology functions. Prior to joining Genmab, Mr. Mancini served in a variety of strategic and operational leadership roles over a nearly 24-year career at Bristol Myers Squibb (BMS). Most recently, he led BMS’ US Innovative Medicines Unit, a team of over 1100 people focused on Immunology & Cardiovascular diseases.
He holds a Bachelor of Science in Biochemistry from the University of Ottawa, Canada, an M.B.A. from Clemson University, South Carolina, USA, and participated in the General Management Program, CEDEP at INSEAD, Fontainebleau, France.
Canadian and Italian
Executive Vice President & Chief Financial Officer
Mr. Pagano joined Genmab in 2007, was appointed Senior Vice President in 2011 and became the Executive Vice President and Chief Financial Officer effective March 1, 2020. Prior to joining Genmab, Mr. Pagano was Corporate Controller and Senior Director of Business Planning at NovaDel Pharma, a publicly traded specialty pharmaceutical company. He started his career at KPMG LLP, reaching the position of Manager, where he provided audit and M&A consulting services to clients ranging from start-ups to Fortune 500s in a broad range of industries.
He is a Certified Public Accountant and received a B.S. in Accounting from The College of New Jersey, as well as an M.B.A. from the Stern School of Business at New York University.
Tahamtan Ahmadi, M.D., Ph.D.
Senior Vice President, Head of Oncology
Dr. Ahmadi joined Genmab in 2017. He holds an M.D. from the University of Cologne (Germany) and a Ph.D. from the University of Freiburg (Germany) and has expertise in translational research, strategic product development, global regulatory submissions and clinical development. Prior to joining Genmab, Dr. Ahmadi was head of experimental medicine and early development oncology at Janssen and a member of the Senior Leadership Team for Oncology.
During his time at Janssen, he led the global development of daratumumab including clinical R&D and medical affairs strategy across indications and was instrumental in the clinical development and initial FDA NDA submission for Ibrutinib. Prior to joining Janssen, Dr. Ahmadi was a faculty member of the Department of Hematology and Oncology at the University of Pennsylvania. Dr. Ahmadi is an author on a number of scientific articles that have been published in journals such as NEJM, Lancet, JCO and Blood, among others.
Iranian-German (U.S. Citizen)
Birgitte Stephensen, M.S.
Senior Vice President, IPR & Legal
Ms. Stephensen joined Genmab in 2002 and was appointed Senior Vice President in 2010. Ms. Stephensen has extensive experience from both private practice and industry working with intellectual property matters within the pharmaceutical and biotech field. Ms. Stephensen passed the European Qualifying Examination as European Patent Attorney in 1994. She earned an M.S. from the Danish University of Pharmaceutical Sciences.
Martine J. van Vugt, Ph.D.
Senior Vice President, Chief of Staff
Dr. van Vugt started her professional career at Genmab in 2001 and was appointed Senior Vice President in 2014. Previously, she was responsible for Genmab’s Project and Alliance Management as well as strategic initiatives and will continue overseeing these areas. Since 2011 she has been active in Business Development. She is listed as inventor on numerous patents and has been involved in the completion of many partnership and research deals between Genmab and big pharma/biotech companies. She holds an M.S. from the University of Wageningen and a Ph.D. from Utrecht University.
Want to get the latest stock information and news about Genmab?
Sound corporate governance
Our corporate governance is at the center of everything we do
Being socially responsible
We are building a sustainable company through business-driven CSR
Turning insights into medicine
See the results of innovation that is rooted in science